Q Chip and ARTES Biotechnology announce collaboration to develop sustained release formulations of therapeutic proteins
The collaboration aims to improve patient compliance and provide a more convenient dosing schedule compared with the current marketed pegylated therapies which require weekly administration. Q Chip will be developing a one month sustained release microsphere formulation This first phase of the collaboration is expected to be completed by the end of 2010.
The study is designed to evaluate Q Chip’s Q-Sphera™ peptide and protein delivery platform to develop a new sustained release microsphere composed of biocompatible polymers. The microsphere will be loaded with interferon alpha 2a manufactured from ARTES´ proprietary yeast Hansenula polymorpha expression system. ARTES will supply interferon alpha 2a and Q Chip will formulate the Q-Sphera microspheres.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.